DelveInsight’s “Mydriasis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Mydriasis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Mydriasis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Mydriasis: An Overview
Mydriasis is the dilation of the pupil, which may be due to a non-physiological cause such as disease, trauma, drug usage, or physiological pupillary response. A mydriatic is an agent that induces dilation of the pupil; it is routinely used to aid the examination of the retina and other deep structures of the eye. In general medical practice, the most frequent indication for pupil dilation is in the screening of diabetic retinopathy followed by macular degeneration.
This condition can be a symptom of an injury to the brain from physical trauma or a stroke and can affect one pupil at a time or both at once. The pupillary dilation pathway is controlled by the iris dilator muscle, which consists of fibers that are oriented radially, and connect the exterior of the iris with the interior. When the dilator muscle contracts, it pulls the interior of the iris outward, thus increasing the size of the pupil. Furthermore, the iris dilator muscle is controlled by the sympathetic nervous system, the part of the autonomic nervous system that is involved in arousal, wakefulness, and the fight or flight response.
Mydriasis Market Key Facts
The total diagnosed prevalent population of Mydriasis in the 7MM countries was estimated to be 8.06 million cases in 2020.
Among the European countries, France had the highest number of cataract surgeries, with approximately 0.88 million procedures in 2020.
Japan had 0.47 million prevalent cases in 2020 which is expected to increase by 2030.
Among the European 5 countries, Spain had the lowest number of cases with 0.36 million procedures in 2020.
As cataract usually affects the aged more than the young, the age-specific cases show peak distribution between 70 and 79 years. In the United States, 1.43 million procedures were performed within this age group (70–79) in 2020.
In 2020, cataract surgery numbers in the US varied according to gender; such as 2.20 million and 1.46 million procedures for females and males, respectively.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Mydriasis market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Mydriasis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Mydriasis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Mydriasis Epidemiology, Segmented as –
Total Prevalent cases of Mydriasis (2019–2032)
Gender-specific cases of Mydriasis (2019–2032)
Age-specific cases of Mydriasis (2019–2032)
Mydriasis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Mydriasis market or expected to be launched during the study period. The analysis covers the Mydriasis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Mydriasis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Mydriasis Market Will Evolve and Grow by 2032 @
Mydriasis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Mydriasis. Currently, Ocuphire Pharma is leading the therapeutics market with its Mydriasis drug candidates in the most advanced stage of clinical development.
Ocuphire Pharma is involved in the development of treatment, Phentolamine Ophthalmic Solution for mydriasis. While some of the companies have recently shifted their focus to this indication, several others are expected to create a significant impact on the market size during the forecast period.
Leading Players in the Mydriasis Therapeutics Market Include
And Many Others
Mydriasis Emerging and Marketed Therapies Covered in the Report Include:
Mydrane: Théa Laboratories
Mydriasert: Théa Laboratories
OMIDRIA: Omeros Corporation
Nyxol: Ocuphire Pharma
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Mydriasis Competitive Intelligence Analysis
4. Mydriasis Market Overview at a Glance
5. Mydriasis Disease Background and Overview
6. Mydriasis Patient Journey
7. Mydriasis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Mydriasis Treatment Algorithm, Current Treatment, and Medical Practices
9. Mydriasis Unmet Needs
10. Key Endpoints of Mydriasis Treatment
11. Mydriasis Marketed Products
12. Mydriasis Emerging Drugs and Latest Therapeutic Advances
13. Mydriasis Seven Major Market Analysis
14. Attribute Analysis
15. Mydriasis Market Outlook (In US, EU5, and Japan)
16. Mydriasis Access and Reimbursement Overview
17. KOL Views on the Mydriasis Market
18. Mydriasis Market Drivers
19. Mydriasis Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Indolent Lymphoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Indolent Lymphoma market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Indolent Lymphoma market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States